BCL2L1 and Thrombocytopenia: Indeed, we found that romiplostim pre-treatment for 4 days prior to the daily administration of the BCL-2 and BCL-XL inhibitor ABT-263 raised platelet production and prevented treatment-induced thrombocytopenia.